Trends in Diseases Reported on US Death Certificates That Mentioned HIV Infection, 1996-2006

Objective: We examined trends during 1996-2006 in diseases reported on death certificates that mentioned HIV infection. Methods: We analyzed multiple-cause mortality data compiled from all US death certificates with any mention of HIV to determine the annual percentages of deaths with various diseases. Results: Deaths reported with HIV during 1996-2006 decreased from 35 340 to 13 750. Standardized percentages of death certificates reporting AIDS-defining opportunistic infections also decreased: pneumocytosis (6.3% to 5.1%), nontuberculous mycobacteriosis (5.5% to 1.8%), cytomegalovirus (5.7% to 1.2%). Non-Hodgkin’s lymphoma rose from 4.8% in 1996 to 6.4% in 1997 and declined to 5.0% in 2001, while Kaposi’s sarcoma declined from 3.7% in 1996 to 1.7% in 2001; these AIDS-defining cancers had stable percentages after 2001. All other cancers increased during 1996-2006 (2.7% to 7.3%). The percentage of deaths with diseases not specifically attributable to HIV increased: liver disease (5.8% to 13.0%), kidney disease (7.9% to 12.0%), and heart disease (4.9% to 10.2%). Conclusion: Among deaths reported with HIV, the percentages reported with HIV-attributable diseases decreased, while the percentages reported with other diseases increased. Consequently, these other life-threatening diseases need more attention in the management of HIV-infected persons.

[1]  G. Satten,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. , 1998, The New England journal of medicine.

[2]  Dr. Ron Short.  Diagnosis? , 1987, The Lancet.

[3]  J. Allison,et al.  Trends in AIDS-defining and non-AIDS-defining malignancies among HIV-infected patients: 1989-2002. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  M. Lederman,et al.  Changing spectrum of mortality due to human immunodeficiency virus: analysis of 260 deaths during 1995--1999. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  R. Byers,et al.  Trends in diseases reported on U.S. death certificates that mentioned HIV infection, 1987-1999. , 2002 .

[6]  R A Israel,et al.  Analytical potential for multiple cause-of-death data. , 1986, American journal of epidemiology.

[7]  R. Selik,et al.  Survival after AIDS diagnosis in adolescents and adults during the treatment era, United States, 1984-1997. , 2001, JAMA.

[8]  J. Ward,et al.  Effects of antiretroviral therapy and opportunistic illness primary chemoprophylaxis on survival after AIDS diagnosis. Adult/Adolescent Spectrum of Disease Group. , 1999, AIDS.

[9]  J. Margolick,et al.  Effectiveness of potent antiretroviral therapies on the incidence of opportunistic infections before and after AIDS diagnosis , 2001, AIDS.

[10]  R. Chaisson,et al.  Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. , 2000, JAMA.

[11]  D. Snydman,et al.  Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  L. Seeff.  Natural history of hepatitis C , 1997, Clinics in liver disease.

[13]  J. Fleishman,et al.  Recent Trends in HIV-Related Inpatient Admissions 1996–2000: A 7-State Study , 2003, Journal of acquired immune deficiency syndromes.

[14]  Mary Young,et al.  Causes of death among women with human immunodeficiency virus infection in the era of combination antiretroviral therapy. , 2002, The American journal of medicine.

[15]  A Muñoz,et al.  Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. , 1998, JAMA.

[16]  J. Portilla,et al.  Drug Toxicity or Syndrome of Immune Restoration Causing Fulminant Cirrhosis After HAART-Induced Immune Recovery , 2002, European Journal of Clinical Microbiology and Infectious Diseases.

[17]  M. McKenna,et al.  Revised surveillance case definitions for HIV infection among adults, adolescents, and children aged <18 months and for HIV infection and AIDS among children aged 18 months to <13 years--United States, 2008. , 2008, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[18]  E. Daugas,et al.  HAART-related nephropathies in HIV-infected patients. , 2005, Kidney international.

[19]  John T Brooks,et al.  Mortality in the Highly Active Antiretroviral Therapy Era: Changing Causes of Death and Disease in the HIV Outpatient Study , 2006, Journal of acquired immune deficiency syndromes.

[20]  N. Crum‐Cianflone,et al.  BK virus-associated renal failure among HIV patients. , 2007, AIDS.

[21]  Mark R Wallace,et al.  Comparisons of Causes of Death and Mortality Rates Among HIV-Infected Persons: Analysis of the Pre-, Early, and Late HAART (Highly Active Antiretroviral Therapy) Eras , 2006, Journal of acquired immune deficiency syndromes.

[22]  K. Buchacz,et al.  Changes in the clinical epidemiology of HIV infection in the United States: Implications for the clinician , 2009, Current infectious disease reports.

[23]  J. Cashman,et al.  HAART drugs induce mitochondrial damage and intercellular gaps and gp 120 causes apoptosis , 2007, Cardiovascular Toxicology.

[24]  S. L. Murphy.  Deaths: final data for 1998. , 2000, National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System.

[25]  M. Chiasson,et al.  Declining HIV/AIDS mortality in New York City. , 1999, Journal of acquired immune deficiency syndromes.

[26]  A. Mocroft,et al.  Changes in the cause of death among HIV positive subjects across Europe: results from the EuroSIDA study , 2002, AIDS.